Topical Drug Delivery Market Size To Attain USD 172.54 Bn By 2030

Published Date : 07 Dec 2022

The global topical drug delivery market was exhibited at USD 102.42 billion in 2022 and is expected to attain around USD 172.54 billion by 2030, growing at a CAGR of 6.7% during the forecast period 2022 to 2030.

The prevalence of skin infections, like psoriasis, and eczema, and minor affections, like acne, are rising and having a big impact on the market, worldwide. According to the National, indigenous, and worldwide epidemiology of psoriasis a methodical analysis and modeling study, the prevalence of psoriasis in grown-ups was estimated to be around30.3 per 100,000 person-years in Taiwan and about321.0 per 100 000 person-years in Italy. Therefore, in various regions, with growth in population sizes, there's a substantial burden related to the skin, which is diagnosed at an initial stage, and in similar cases, the content of drug delivery becomes more important. Hence, these statistics show that skin complaint frequency is growing at a faster pace and is getting a global burden, which is likely to appreciatively propel the growth of the topical drug delivery market. 

Report Highlights

  • On the basis of the route of administration, the oral drug delivery segment is estimated for the largest share of the market of pharmaceutical drug delivery. The large share of this market segment is due to the drug administration's convenience via the oral route, cost-effectiveness, patient preference, and ease of large-scale production of oral dosage forms.
  • On the basis of application, the segment named infectious diseases is estimated for the largest share of the market of pharmaceutical drug delivery. The major share of this market segment is dominating due to the rising number of FDA approvals for similar drugs and adding R&D expenditure for new drugs owing to the current COVID-19 epidemic script.

Topical Drug Delivery Market Report Scope

Report Coverage Details
Market Size In 2022 USD 102.42 Billion
Market Size By 2030 USD 172.54 Billion
Growth Rate from 2022 to 2030 CAGR of 6.7%
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered By Product, By Route of Administration, By Application, By End User
Regions Covered North America, Europe, Asia-Pacific, Latin America, Middle East and Africa

Regional Insight

North America has accounted for the dominating share in the topical drug delivery market. Due to the COVID-19 outbreak, the market is awaiting to observe positive growth. This is substantially due to the new treatment being developed. For case, in August 2020, the United States Food and Drug Administration approved an untoward ointment,' T3X' developed by Advanced Penetration Technology. It has been approved against the SARS-CoV-2 contagion. Furthermore, the studies have also shown that T3X was suitable successfully in order to kill the contagion in 30 seconds, owing to factors, similar to the availability of a large number of pharmaceutical companies and drug delivery technology providers. As per the data handed by GLOBOCAN, 2020, new cases of melanoma skin cancer were reported in the North American region, which is anticipated to reach 142,000 by the time 2040. This growing burden of skin-related conditions is anticipated to accelerate market growth. 

Likewise, growing product launches are also anticipated to boost the market growth in this region. For case, in August 2020, the United States Food and Drug Administration (US FDA) approved Winlevi (clascoterone cream 1) developed by CassiopeaSpA for the treatment of acne. Therefore, the factors mentioned over are anticipated to thrive the market growth in this region during the cast period.

Market Dynamics 

Driver: High prevalence of skin diseases

According to the Project of Global Burden of Disease, skin diseases similar as eczema, psoriasis, skin cancer, and vitiligo continue to be among the leading nonfatal disease burden cause around the world and affect a huge proportion of the global population. Likewise, the frequency of psoriasis worldwide ranges between 0.09% and 11.4%, making it a serious global problem with at least 100 million individuals affected worldwide. As topical drug delivery is the first line of treatment for the maturity of skin conditions, the demand for advanced topical products is anticipated to increase in the coming times.

Restraint: Preference for alternative modes of drug delivery

Several alternative drug delivery modes are available for end users and patients. In addition, the alternatives over topical drug delivery benefits form a major restraint for the market growth. Of these, the oral route is the most preferred as it's easy to use, accessible, cost-effective, safe, and respectable. Likewise, orally administered drugs can be accessibly stored and are provident, movable, noninvasive, and safe. No special training is needed for the administration of these drugs as compared to topical phrasings. Injectables also witnessed widespread usage for illustration, insulin injections for diabetics to tone-administer. 

Opportunity: Delivery of biologics through the transdermal route 

The delivery of biologics through the transdermal route is one of the arising trends in the topical drug delivery market. The transdermal delivery of large motes as a volition to subcutaneous, intramuscular, or intravenous routes of administration is anticipated to give significant patient benefits, similar as cost-effective treatment and painless drug delivery. 

Challenge: Technical barriers related to skin irritation and permeability 

The potential for local adverse responses and skin irritation is a substantial challenge for topical drug delivery transdermal and formulation systems. Still, the advent of new skin permeation methods and the development of methods in order to reduce irritation on the skin would help broaden the topical drug delivery formulation and transdermal systems market or macromolecules, hydrophilic composites, and conventional drugs for new therapeutic indications. 

Key Players in the Report:

  • Johnson & Johnson
  • Novartis International AG
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • Bayer AG
  • Antares Pharma, Inc.
  • GlaxoSmithKline plc
  • 3M (US), Merck & Co., Inc.
  • Sanofi
  • Amgen, Inc.

Market Segmentation

By Product

  • Semi-Solid Formulations
    • Creams
    • Ointments
    • Lotions
    • Gels
    • Pastes
  • Liquid Formulations
    • Solutions
    • Suspensions
  • Solid Formulations
    • Powders
    • Suppositories
  • Transdermal Products
    • Transdermal Patches
    • Transdermal Semi-solids

By Route of Administration

  • Oral
  • Injectable
  • Topical
  • Ocular
  • Pulmonary
  • Implantable
  • Transmucosal
  • Nasal

By Application

  • Infectious Diseases
  • Cancer
  • Cardiovascular Diseases
  • Diabetes
  • Respiratory Diseases
  • Central Nervous System Disorders
  • Autoimmune Diseases
  • Other Applications

By End User

  • Home Care Settings
  • Hospitals & Clinics
  • Burn Centers
  • Other Facilities

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333